CanSino Biologics announced that it has received the Drug Registration Certificate from the National Medical Products Administration for its adsorbed tetanus vaccine. The vaccine is mainly used for the prevention of tetanus in non-neonates, and is produced using animal-free culture media. Phase III clinical data showed immunogenicity superior to the control vaccine. The company has entered into an exclusive commercialization cooperation agreement with Grand Life Sciences for the vaccine, authorizing it to provide exclusive promotion services in Greater China. The launch of this product will enrich the company's commercial product portfolio, expand its presence in the adult vaccine market, and have a positive impact on its performance.
Cansino Biologics IncReceived drug registration certificate for tetanus vaccine, with Phase III data showing superior immunogenicity.
